PEG-asparaginase (Oncaspar) 2500 U/m2 BSA in reinduction and relapse treatment in the ALL/NHL-BFM protocols
详细信息 查看全文
- 作者：Hans-Joachim M¨¹ller ; Rita Beier ; Jo?o da Palma ; Claudia Lanvers ; Elvira Ahlke ; Volker von Sch¨¹tz ; Martin Gunkel ; Alexander Horn ; Martin Schrappe and G¨¹nter Henze ; et al.
- 刊名：Cancer Chemotherapy and Pharmacology
- 出版年：2002
- 出版时间：February 2002
- 年：2002
- 卷：49
- 期：2
- 页码：149-154
- 全文大小：141 KB
文摘
Purpose: As previous data had shown that only two-thirds of patients had the predicted activity time courses when PEG-asparaginase 1000 U/m2 was used in reinduction after native E. coli asparaginase in induction treatment of acute lymphoblastic leukaemia (ALL), drug monitoring was performed with the use of a higher dose. Methods: Because one-third of patients had insufficient serum asparaginase activity time courses after a single dose of 1000 U/m2 PEG-asparaginase during reinduction treatment, a dose of 2500 U/m2 PEG-asparaginase, which is the approved dosage in Germany, was used in 39 reinduction and 20 relapse patients to determine whether prolongation of the activity time course may be possible with this higher dose, and to look for significant differences between reinduction and relapse patients. Results: After 1, 2 and 3 weeks, the mean activities were 1113늃 U/l, 231냋 U/l, and 13ᆷ U/l in the reinduction patients, and 1078뉑 U/l, 165낋 U/l and 19ᆰ U/l in the relapse patients, respectively. There were a considerable number of patients with a substantially shortened activity time course in both groups. In 10 of 39 reinduction patients and in 7 of 24 doses during relapse treatment, only activities <100 U/l were found after 1 week with a further fast decline. No statistically significant differences between the two patient groups could be shown at any time-point. Conclusions: Comparison of these data with activities after 1000 U/m2 PEG-asparaginase showed no prolongation of the time with activity in the therapeutic range with the higher dose. Therefore, for a longer duration of therapeutic activity, administration of further doses is mandatory.